| Literature DB >> 25360767 |
Kuo-Hung Huang1, Yuan-Tzu Lan2, Wen-Liang Fang3, Jen-Hao Chen4, Su-Shun Lo5, Anna Fen-Yau Li6, Shih-Hwa Chiou7, Chew-Wun Wu3, Yi-Ming Shyr3.
Abstract
BACKGROUND: Minimally invasive surgery, including laparoscopic and robotic gastrectomy, has become more popular in the treatment of gastric cancer. However, few studies have compared the learning curves between laparoscopic and robotic gastrectomy for gastric cancer.Entities:
Mesh:
Year: 2014 PMID: 25360767 PMCID: PMC4216064 DOI: 10.1371/journal.pone.0111499
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Comparison of the clinicopathological differences between laparoscopic and robotic gastrectomy for gastric cancer.
| Laparoscopicgastrectomyn = 73 | Roboticgastrectomyn = 72 |
| |
| Age (years) | 66.0±13.5 | 67.7±15.1 | 0.465 |
| Gender (M/F) | 42/31 | 40/32 | 0.868 |
| Tumor size (cm) | 3.3±1.6 | 3.2±1.5 | 0.688 |
| BMI (kg/m2) | 24.2±3.3 | 24.1±3.3 | 0.865 |
| Resection extent | |||
| Subtotal/total gastrectomy | 63/10 | 64/8 | 0.802 |
| Reconstruction method | 0.001 | ||
| Intracorporeal anastomosis (Billroth-I) | 22 (30.1) | 6 (8.3) | |
| Extracorporeal anastomosis (Roux-en-Y or uncut R-Y) | 51 (69.9) | 66 (91.7) | |
| Extent of lymphadenectomy | |||
| D1+α/D1+β/D2 | 17/15/41 | 0/5/67 | <0.001 |
| Retrieved LN number | 28.1±11.0 | 30.6±12.6 | 0.202 |
| Pathological T category | 0.757 | ||
| T1/T2/T3/T4 | 49/10/11/3 | 52/9/10/1 | |
| Pathological N category | 0.228 | ||
| N0/N1/N2/N3 | 55/10/3/5 | 50/8/10/4 | |
| Pathological TNM stage | 0.537 | ||
| IA/IB | 42/8 | 41/8 | |
| IIA/IIB | 12/6 | 15/1 | |
| IIIA/IIB/IIIC | 3/2/0 | 4/2/1 | |
| Medical cost (US dollars) | 2915.1±1341.4 | 5714.2±1591.7 | <0.001 |
BMI: body mass index; LN: lymph node.
Operative outcomes of gastric cancer patients who underwent laparoscopic or robotic gastrectomy.
| LaparoscopicGastrectomyn = 73 | RoboticGastrectomyn = 72 |
| |
| Operative outcomes | |||
| Operative time (min) | 319.8±113.7 | 357.9±107.8 | 0.040 |
| Operative blood loss (mL) | 116.0±135.3 | 79.6±77.1 | 0.049 |
| Postoperative hospital stay (day) | 13.2±11.1 | 11.0±11.8 | 0.256 |
| Surgical morbidity | 6 (8.2) | 9 (12.5) | 0.587 |
| Anastomosis leakage | 3 (4.1) | 3 (4.2) | |
| Anastomosis stenosis | 1 (1.4) | 0 | |
| Delayed gastric emptying | 4 (5.5) | 5 (6.9) | |
| Chylous leakage | 1 (1.4) | 1 (1.4) | |
| Wound infection | 0 | 1 (1.4) | |
| Intraabdominal abscess | 2 (2.7) | 2 (2.8) | |
| Intestinal obstruction | 0 | 1 (1.4) | |
| Mortality | 1 (1.4) | 1 (1.4) | 1.000 |
Some patients had more than one comorbidity.
Data were presented as mean±SD or n (%).
Figure 1The operative time of laparoscopic and robotic gastrectomy decreased significantly after the learning curves.
(A) The operative time of laparoscopic gastrectomy decreased after the 41th case. The arrows show the case number of robotic gastrectomy (RG) performed at the corresponding time of laparoscopic gastrectomy. (B) The operative time and docking time of robotic gastrectomy decreased after the 25th case.
Comparison of the surgical performance and operative outcomes between laparoscopic and robotic gastrectomy in the learning curve.
| Laparoscopic gastrectomy n = 41 | Robotic gastrectomy n = 25 |
| |
| Operative time (min) | 393.9±70.8 | 467.0±75.2 | <0.001 |
| Extent of lymphadenectomy (D1+α/D1+β/D2) | 17/14/10 | 0/4/21 | <0.001 |
| Retrieved LN number | 26.2±11.5 | 31.0±13.7 | 0.124 |
| Blood loss (mL) | 164.9±159.6 | 92.0±88.0 | 0.040 |
| Postoperativehospital stay (day) | 15.5±12.7 | 12.7±17.4 | 0.453 |
| Surgical morbidity | 6 (14.6) | 5 (20) | 0.735 |
| Surgical mortality | 1 (2.4) | 1 (4) | 1.000 |
| Medical cost (US dollars) | 2787.6±1600 | 4259.5±1046.3 | <0.001 |
LN: lymph node.
Data were presented as mean±SD or n (%).
Comparison of the clinicopathological differences and operative outcomes between laparoscopic and robotic gastrectomy for gastric cancer after the learning curve.
| Laparoscopicgastrectomyn = 32 | RoboticGastrectomyn = 47 |
| |
| Age (years) | 64.8±12.6 | 68.2±15.7 | 0.308 |
| Gender (M/F) | 15/17 | 29/18 | 0.250 |
| Tumor size (cm) | 3.6±1.7 | 3.2±1.4 | 0.207 |
| BMI (kg/m2) | 23.3±3.5 | 23.7±3.4 | 0.560 |
| Resection extent | |||
| Subtotal/total gastrectomy | 28/4 | 44/3 | 0.432 |
| Reconstruction method | 0.001 | ||
| Intracorporeal anastomosis | 22 (68.8) | 6 (12.8) | |
| (Billroth-I) | |||
| Extracorporeal anastomosis | 10 (31.3) | 41 (87.2) | |
| (Roux-en-Y or uncut R-Y) | |||
| Extent of lymphadenectomy | |||
| D1+ β/D2 | 31/1 | 46/1 | 1.000 |
| Retrieved LN number | 30.6±10.0 | 30.±12.1 | 0.935 |
| Operative time (min) | 229.7±88.3 | 286.9±57.2 | <0.001 |
| Blood loss (mL) | 52.7±50.2 | 73.0±70.8 | 0.176 |
| Postoperative hospital stay (day) | 10.4±7.9 | 10.2±7.3 | 0.873 |
| Surgical morbidity | 2 (6.3) | 4 (8.5) | 1.000 |
| Medical cots (US dollars) | 3083.6±890.8 | 6488.0±1256 | <0.001 |
| Pathological T category | 0.182 | ||
| T1/T2/T3/T4 | 16/4/9/3 | 34/4/8/1 | |
| Pathological N category | 0.318 | ||
| N0/N1/N2/N3 | 20/5/3/4 | 33/4/8/2 | |
| Pathological TNM stage | 0.221 | ||
| IA/IB | 12/3 | 28/3 | |
| IIA/IIB | 7/5 | 10/1 | |
| IIIA/IIB/IIIC | 3/2/0 | 2/2/1 |
BMI: body mass index; LN: lymph node.